Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 vs Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT06118333Phase 3Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Dec 2023
- Primary completion
- Nov 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab brengitecan in nasopharyngeal carcinoma (NPC), sponsored by Biokin Pharmaceutical. Started Dec 2023; status: active, not recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06118333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06118333.